Enzon Pharmaceuticals Files 8-K on Shareholder Nominations
Ticker: ENZN · Form: 8-K · Filed: Jul 2, 2024 · CIK: 727510
Sentiment: neutral
Topics: corporate-governance, shareholder-action, filing
TL;DR
Enzon Pharma filed an 8-K about shareholder nominations - board changes might be brewing.
AI Summary
Enzon Pharmaceuticals, Inc. filed an 8-K on July 2, 2024, to report on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing details the company's structure and reporting information, including its incorporation in Delaware and its principal executive offices located at 20 Commerce Drive, Suite 135, Cranford, New Jersey.
Why It Matters
This filing indicates potential changes or discussions regarding the company's board of directors, which could impact its strategic direction and governance.
Risk Assessment
Risk Level: medium — Filings related to shareholder nominations can signal potential activism or changes in corporate governance, which may introduce uncertainty.
Key Numbers
- 001-36435 — Commission File Number (Identifies the company's SEC filings)
- 22-2372868 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- ENZON PHARMACEUTICALS, INC. (company) — Registrant
- July 2, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 20 Commerce Drive, Suite 135, Cranford, New Jersey (address) — Address of principal executive offices
- Exchange Act Rule 14a-11 (regulation) — Subject of the filing
FAQ
What specific shareholder nominations are being reported in this 8-K filing?
The filing states it is a report on shareholder nominations pursuant to Exchange Act Rule 14a-11, but the specific names of the nominees are not detailed within the provided text.
When was the earliest event reported in this filing?
The earliest event reported was on July 2, 2024.
In which state is Enzon Pharmaceuticals, Inc. incorporated?
Enzon Pharmaceuticals, Inc. is incorporated in Delaware.
What is the address of Enzon Pharmaceuticals' principal executive offices?
The address is 20 Commerce Drive, Suite 135, Cranford, New Jersey.
What specific section of the Exchange Act is referenced in relation to shareholder nominations?
The filing references Exchange Act Rule 14a-11.
Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2024-07-02 16:30:44
Filing Documents
- tm2418795d1_8k.htm (8-K) — 23KB
- 0001104659-24-077371.txt ( ) — 185KB
- enzn-20240702.xsd (EX-101.SCH) — 3KB
- enzn-20240702_lab.xml (EX-101.LAB) — 33KB
- enzn-20240702_pre.xml (EX-101.PRE) — 22KB
- tm2418795d1_8k_htm.xml (XML) — 3KB
08
Item 5.08 Shareholder Director Nominations. The Board of Directors (the "Board") of Enzon Pharmaceuticals, Inc. (the "Company") has established September 26, 2024, as the date for the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The Board also established August 13, 2024, as the record date for the Annual Meeting. Due to the fact that the Company is now holding its Annual Meeting more than 25 days from June 8, 2024, the Company is providing the due date for submission of any qualified stockholder proposal or director nominations. In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Company's bylaws (the "Bylaws"), the deadline for receipt of stockholder proposals or nominations for inclusion in the Company's proxy statement for the Annual Meeting pursuant to Rule 14a-8 will be no later than July 12, 2024 and must be received by the Company's secretary at 20 Commerce Drive, Suite 135, Cranford, New Jersey, 07016 no later than such date. Stockholder proposals must comply with all of the applicable requirements set forth in the rules and regulations of the Securities and Exchange Commission, including Rule 14a-8 under the Exchange Act and the Bylaws.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZON PHARMACEUTICALS, INC. (Registrant) Date: July 2, 2024 By: /s/ Richard L. Feinstein Name: Richard L. Feinstein Title: Chief Executive Officer, Chief Financial Officer and Secretary